LFCR Lifecore: רווח נקי למניה בארבעת הרבעונים האחרונים

The visual price representation available on the GURU.Markets platform demonstrates the EPS (TTM) dynamics for Lifecore Biomedical (LFCR), which currently stands at -429.10. The Lifecore Biomedical (LFCR) business relies on the implementation of AI and robotics in biopharmaceutical production to reduce costs. While geopolitical conflicts and sanctions hinder the international import of raw materials, the company's unique sterile injectable manufacturing capacities protect Lifecore Biomedical (LFCR) from aggressive pricing pressure from competitors.

For Lifecore Biomedical (LFCR), this indicator reflects the monetization efficiency of its unique CDMO capacities within the injectables segment. The 12-month EPS annual growth rate is calculated as the percentage change in earnings per share over the last four quarters relative to the same period last year. The growth of this metric confirms the company's ability to convert strict FDA standards into financial results. The stability of this figure underscores the high switching costs for customers moving to other manufacturers.